Mirum Pharmaceuticals (NASDAQ:MIRM) Research Coverage Started at Raymond James

Raymond James began coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a research report released on Monday morning, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $28.00 price objective on the stock.

A number of other equities analysts also recently issued reports on the company. Guggenheim started coverage on Mirum Pharmaceuticals in a report on Monday. They issued a buy rating and a $18.00 price target for the company. Evercore ISI started coverage on Mirum Pharmaceuticals in a report on Monday. They issued an outperform rating and a $25.00 price target for the company. Finally, Citigroup started coverage on Mirum Pharmaceuticals in a report on Monday. They issued a buy rating and a $21.00 price target for the company. Five equities research analysts have rated the stock with a buy rating, The company presently has an average rating of Buy and a consensus price target of $25.00.

Shares of Mirum Pharmaceuticals stock opened at $13.45 on Monday. Mirum Pharmaceuticals has a one year low of $12.05 and a one year high of $15.50.

In other news, Director Patrick J. Heron acquired 450,000 shares of Mirum Pharmaceuticals stock in a transaction on Monday, July 22nd. The stock was bought at an average price of $15.00 per share, for a total transaction of $6,750,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider James E. Flynn acquired 332,000 shares of Mirum Pharmaceuticals stock in a transaction on Monday, July 22nd. The stock was purchased at an average price of $15.00 per share, with a total value of $4,980,000.00. The disclosure for this purchase can be found here. Insiders purchased 1,357,000 shares of company stock valued at $20,355,000 over the last ninety days.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

Recommended Story: What is a Buy-Side Analyst?

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.